Lantus (Insulin Glargine) Side Effects: Severity by Patient Phenotype

What Side Effects Does Lantus Cause, and How Severe Are They?

Lantus (insulin glargine 100 units/mL, manufactured by Sanofi) causes a spectrum of adverse effects that the FDA label groups into very common, common, uncommon, and rare categories. Hypoglycemia is by far the most frequent concern, but injection-site reactions, weight gain, and rare immune responses also appear. Severity depends heavily on your phenotype: your diabetes type, body composition, kidney function, hormonal status, and where you are in your reproductive life.

The FDA-approved prescribing information for Lantus lists hypoglycemia as the most common adverse reaction, followed by injection-site reactions (including pain, redness, and lipodystrophy), weight gain, peripheral edema, and allergic reactions.

The Severity Spectrum at a Glance

Side effects in clinical practice fall into three severity tiers.

Tier 1 (mild, self-limiting): Injection-site pain, mild hypoglycemia correctable with oral glucose, minor skin reactions, and transient ankle edema. These affect the largest share of patients and rarely require stopping Lantus.

Tier 2 (moderate, clinically significant): Nocturnal hypoglycemia requiring assistance, lipohypertrophy from repeated injection in the same site, and meaningful weight gain (averaging around 1.8 kg over 24 weeks in the LAPTOP trial comparing detemir to glargine in type 2 diabetes). These often prompt dose or lifestyle adjustments.

Tier 3 (severe or rare, potentially life-threatening): Severe hypoglycemia with loss of consciousness, anaphylaxis, generalized urticaria, angioedema, and hypoglycemia-induced cardiovascular events. These are uncommon in absolute terms but carry serious consequences.

Hypoglycemia: The Side Effect That Matters Most

Hypoglycemia is the dose-limiting side effect of every insulin, and glargine is no exception. The risk level varies by phenotype in ways that matter specifically to women.

Rates in Clinical Trials

In the ORIGIN trial, which enrolled 12,537 participants with early type 2 diabetes or prediabetes, severe hypoglycemia (defined as requiring third-party assistance) occurred at a rate of approximately 1.05 episodes per 100 patient-years in the glargine arm versus 0.30 in the standard-care arm. That trial provided the most granular long-term hypoglycemia data available for glargine, running over a median of 6.2 years. The absolute risk remained low, but the relative increase was real and clinically meaningful.

Nocturnal hypoglycemia is the variant women most often describe as distressing. A pooled analysis published in Diabetes Care found that nocturnal symptomatic hypoglycemia rates with glargine were roughly 25% lower than with NPH insulin, one of the reasons clinicians favor basal analogs over older insulins.

How Your Menstrual Cycle Changes Your Risk

Insulin sensitivity is not constant across your cycle. During the follicular phase (days 1 through 14 roughly), estrogen tends to improve insulin sensitivity. In the luteal phase, progesterone acts as a counter-regulatory hormone that reduces insulin sensitivity, so the same Lantus dose that worked perfectly in week 1 may leave you running slightly high in week 3.

The flip side: the follicular-phase insulin-sensitivity window can raise hypoglycemia risk if you do not adjust your dose or carbohydrate intake. A review in the Journal of Diabetes Science and Technology documented these cycle-dependent fluctuations and noted that women with type 1 diabetes frequently require 10-20% dose adjustments across their cycle. Data for type 2 diabetes women on basal insulin alone are thinner; this is one area where evidence is largely extrapolated from type 1 populations.

Menopause and Hypoglycemia Unawareness

Post-menopausal women face a compounding problem. Estrogen normally amplifies adrenergic symptoms like sweating, tremor, and palpitations that alert you to falling blood glucose. After menopause, those signals are blunted. Research published in Menopause demonstrated that post-menopausal women with type 1 diabetes had significantly higher rates of impaired hypoglycemia awareness compared to pre-menopausal women. The same physiological mechanism applies to type 2 diabetes patients on insulin. If you are post-menopausal and on Lantus, discuss whether continuous glucose monitoring (CGM) would help you catch asymptomatic lows.

PCOS and Hypoglycemia Thresholds

Women with PCOS often start insulin management after failing or intolerating metformin, or they use glargine alongside metformin. Insulin resistance is the biochemical core of PCOS for most phenotypes, which means your effective dose of Lantus may be higher than average. Higher doses carry higher hypoglycemia risk when food intake drops, exercise increases, or concurrent medications change.

Injection-Site Reactions and Lipodystrophy

Injection-site reactions, covering pain, bruising, redness, pruritus, and lipodystrophy (both lipoatrophy and lipohypertrophy), affect a meaningful minority of users. The Lantus prescribing label reports injection-site reactions in approximately 4% of clinical trial participants.

Lipohypertrophy deserves specific attention because it directly impairs insulin absorption. Injecting repeatedly into the same spot causes subcutaneous fat to accumulate, creating a lump that absorbs insulin unpredictably. A study in Diabetes, Obesity and Metabolism found that patients with lipohypertrophy had significantly higher HbA1c levels and greater glycemic variability than those without, entirely attributable to inconsistent absorption.

Rotating injection sites across a region, rather than simply between abdomen, thigh, and arm, prevents this complication. Use a new spot at least 1 cm from the previous injection each day.

Weight Gain: How Much, and Why It Matters for Women

Weight gain with basal insulin initiation is a documented, consistent finding. In a 2014 meta-analysis in Diabetes Research and Clinical Practice, patients initiating basal insulin gained an average of 1.8 to 2.1 kg over 24 weeks. The mechanism involves two factors: improved glycemic control reducing glucose-calorie losses in urine, and the anabolic effect of insulin on adipose tissue.

For women specifically, this weight gain lands differently.

Body Composition and Hormonal Context

Women store a greater proportion of weight as subcutaneous fat compared to men, and estrogen modulates where fat is deposited. In perimenopause and post-menopause, estrogen decline shifts fat deposition toward visceral adipose tissue, which is more metabolically adverse. If you are starting Lantus during perimenopause, the concurrent hormonal shift may amplify the weight-gain effect beyond what trial data predict for a mixed-sex population.

Women with PCOS already carry excess visceral adiposity and elevated cardiovascular risk. Even a 1-2 kg gain from insulin initiation may worsen insulin resistance further, creating a cycle that warrants close monitoring. Discuss whether concurrent GLP-1 receptor agonist therapy (which is weight-neutral to weight-reducing) would be appropriate for your phenotype.

Strategies to Minimize Weight Gain

Titrating your Lantus dose to the minimum effective dose (using a fasting glucose target of 80-100 mg/dL per standard basal titration algorithms), maintaining consistent carbohydrate intake, and prioritizing resistance training all reduce the net weight impact. No specific women-only trial has tested these strategies in isolation with glargine; this is a gap in the evidence.

Rare but Serious: Allergic Reactions and Anaphylaxis

Systemic allergic reactions to insulin glargine are rare, but reports exist in the FDA Adverse Event Reporting System (FAERS) and in the published post-market literature. The Lantus label carries a warning for severe, life-threatening allergic reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock.

Localized injection-site allergy (a raised, itchy wheal appearing within minutes and resolving within an hour) is more common and usually self-limiting. Systemic reactions, presenting with urticaria spreading beyond the injection site, throat tightening, or hemodynamic instability, require immediate epinephrine and emergency care.

If you notice generalized skin reactions, facial swelling, or difficulty breathing within minutes to an hour of injecting, call emergency services. Do not wait to see whether symptoms resolve on their own.

Women with a history of multiple drug allergies or who are using insulin for the first time have a slightly elevated vigilance requirement for allergic responses, though absolute risk remains very low.

Peripheral Edema

Insulin causes sodium and water retention through its action on renal tubular sodium transporters. This produces peripheral edema, most noticeable around the ankles, particularly in the first few weeks of starting or up-titrating Lantus.

In a pooled analysis of glargine key trials, edema was reported in approximately 5-7% of participants. It is usually mild and self-resolving, but if you have underlying heart failure, nephrotic syndrome, or severe venous insufficiency, the fluid retention may be clinically significant enough to require adjustment of concurrent diuretics or careful dose titration.

During pregnancy, distinguishing insulin-related edema from physiological gestational edema or preeclampsia is a clinical priority. See the pregnancy section below.

Pregnancy, Lactation, and Contraception: What You Need to Know

Pregnancy compatibility: Insulin glargine is not contraindicated in pregnancy, but the evidence base from human studies is narrower than many women and clinicians assume. The FDA does not use the old A/B/C/D/X letter system for drugs approved after 2015, and glargine falls under the current labeling rule requiring narrative risk summaries.

The 2019 ACOG Practice Bulletin on Pregestational Diabetes recommends human insulin (NPH or regular) as the preferred agent in pregnancy because of a longer safety record. It acknowledges that insulin analogs including glargine are used and that available data have not demonstrated clear harm, but notes that controlled human trial data specific to pregnancy are limited.

The GLAT trial compared glargine to NPH in pregnant women with type 1 diabetes and found similar maternal and neonatal outcomes, with no signal of teratogenicity. The TOTEM.net registry study similarly found no excess congenital anomaly rate with first-trimester glargine exposure compared to NPH. These are observational data; no large randomized controlled trial has been powered specifically to assess congenital anomaly risk.

Practical guidance during pregnancy:

• If you are already well-controlled on Lantus before conception, many clinicians continue it rather than switching to NPH mid-pregnancy, balancing the known disruption of a regimen change against theoretical risks.
• Insulin requirements increase substantially through the second and third trimesters, often by 50-100% over pre-pregnancy doses, due to placental hormone production and increasing maternal weight.
• Hypoglycemia risk is highest in the first trimester, when nausea and vomiting reduce carbohydrate intake but insulin needs have not yet risen substantially. This is when severe hypoglycemia episodes are most common in pregnant women with type 1 diabetes, according to data from the Diabetes in Pregnancy Network.

Lactation: Insulin is a large peptide molecule. It does not transfer meaningfully into breast milk, and any amount that did transfer would be destroyed by the infant's gastrointestinal tract before absorption. The LactMed database classifies insulin as compatible with breastfeeding. Your insulin dose will likely drop rapidly postpartum as placental hormones clear, and you will need close monitoring to avoid postpartum hypoglycemia.

Contraception note: Lantus itself does not require contraception, unlike true teratogens. However, if you have type 1 or type 2 diabetes that is poorly controlled, unintended pregnancy carries high risk. Using reliable contraception until your HbA1c is below 8% (64 mmol/mol) is standard pre-conception guidance from ACOG.

Who Is at Highest Risk for Severe Side Effects?

Not every woman on Lantus carries the same side-effect risk. The table below maps patient phenotype to the side effects most likely to be clinically significant for that phenotype.

| Phenotype | Highest-priority side effect | Why | |---|---|---| | Reproductive-age woman with type 1 diabetes | Nocturnal hypoglycemia, cycle-driven dose instability | Progesterone-estrogen swings alter insulin sensitivity week to week | | Woman with PCOS on insulin | Weight gain, hypoglycemia after dose increases | High baseline insulin resistance means higher required doses | | Pregnant woman | Severe hypoglycemia (first trimester), dose escalation needs | Nausea reduces intake; placental hormones drive resistance | | Postpartum woman breastfeeding | Postpartum hypoglycemia | Rapid drop in placental hormones; caloric demands of lactation | | Peri- and post-menopausal woman | Hypoglycemia unawareness, weight gain landing as visceral fat | Estrogen loss blunts adrenergic warning signals | | Woman with type 2 diabetes and CKD | Hypoglycemia (prolonged) | Reduced renal insulin clearance extends drug action | | Elderly woman with type 2 diabetes | Falls from hypoglycemia | Blunted awareness plus orthostatic instability |

Who Lantus Is and Is Not Right For

Lantus is appropriate for women who need stable, once-daily basal insulin coverage with a low peak and long duration. It works well for type 1 diabetes at any life stage and for type 2 diabetes where oral agents and GLP-1 agonists have not achieved target glycemia.

It is a less optimal choice in these circumstances.

Think carefully with your clinician if:

• You are pregnant and your team prefers NPH for its longer evidence record.
• You have significant injection-site lipohypertrophy that is impeding absorption.
• You are post-menopausal with documented hypoglycemia unawareness and no access to CGM.
• You have severe renal impairment (eGFR <30 mL/min/1.73 m²), where dose adjustments and close monitoring are essential.

Lantus is specifically not recommended if:

• You are having an episode of hypoglycemia (self-evident, but worth stating: never inject basal insulin during active hypoglycemia).
• You are hypersensitive to insulin glargine or any of its excipients.

Managing Side Effects: Practical Steps

For Hypoglycemia

Follow the 15-15 rule for mild events: consume 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice), wait 15 minutes, and recheck your blood glucose. For severe events where you cannot self-treat, glucagon (nasal powder or auto-injector) must be available to someone in your household. The American Diabetes Association Standards of Care 2024 recommends prescribing glucagon for all patients on insulin.

If you are having more than two episodes of mild hypoglycemia per week, contact your clinician to discuss dose reduction.

For Injection-Site Reactions

Rotate sites systematically. Room-temperature insulin stings less than cold insulin. Use a new needle for each injection; reused needles have blunted tips that increase tissue trauma. If you develop a persistent raised lump, avoid that area entirely for at least four to six weeks.

For Weight Gain

A registered dietitian (RD) experienced in diabetes can help offset the anabolic effect of insulin through meal composition adjustments that do not require caloric restriction so severe it causes hypoglycemia. This balance is harder in the perimenopausal years when metabolic rate is already declining.

What the FDA Adverse Event Reporting System Tells Us

FAERS data through 2023 show that the most common serious adverse events reported for Lantus include hypoglycemia, hypoglycemic coma, and hypoglycemic seizure. Allergic events including anaphylaxis, angioedema, and generalized urticaria appear far less frequently but are consistently present across reporting years.

One documented pattern in FAERS: medication errors, particularly confusion between Lantus (100 units/mL) and Toujeo (insulin glargine 300 units/mL), have led to three-fold overdoses and severe hypoglycemia. If you are switching between glargine products, confirm the concentration with your pharmacist before the first injection. The FDA issued a drug safety communication specifically about this confusion risk.

A Note on the Evidence Gap for Women

Women have been under-represented in insulin trials historically. The ORIGIN trial, the largest long-term glargine RCT, enrolled approximately 35% women, which is better than older cardiovascular drug trials but still means the sex-specific subgroup analyses are underpowered for detecting moderate differences in side-effect rates between women and men. Cycle-dependent dose variability, the interaction between menopause and hypoglycemia awareness, and weight-gain distribution in women have been studied primarily through smaller observational studies and extrapolation from type 1 diabetes research. Where the evidence is direct, this article has said so. Where it is extrapolated, that is also stated.